Q3161222 (Q3161222): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Allogeneic transplantation is the only therapeutic option for many patients with malignant haemopathies. Its results are limited by its high toxicity, with graft-versus-host disease (GHD) being the main cause of morbidity and mortality. GVHD occurs in 30-70 % of patients; of these up to 80 % do not respond or relapse after first line of treatment (corticoids), and their survival does not exceed 15 % in most studies. Mesenchymal stromal cells (MS...) |
||||||||||||||
| Property / summary | |||||||||||||||
Allogeneic transplantation is the only therapeutic option for many patients with malignant haemopathies. Its results are limited by its high toxicity, with graft-versus-host disease (GHD) being the main cause of morbidity and mortality. GVHD occurs in 30-70 % of patients; of these up to 80 % do not respond or relapse after first line of treatment (corticoids), and their survival does not exceed 15 % in most studies. Mesenchymal stromal cells (MSCs) have been used with mixed results in the treatment of acute GVHD. Some members of this Consortium have developed two previous clinical trials in which they demonstrated that: 1. It is possible to use in clinic MSCs expanded from bone marrow in the absence of bovine serum, which avoids potential risks of zoonoses and 2. since the effect of MSCs on the immune system is transient, sequential administration of MSCs may increase their efficacy. In this sense, it is unknown which is the best administration pattern or which is the best source of MSCs, which can also be easily isolated from adipose tissue (lipoaspirates, usually discarded) (Ad-MSCs). Finally, after infusion, MSCs disappear quickly, so it will be important to increase their therapeutic efficacy through mechanisms that favor their migration and immunosuppressive effect on target organs of GVHD. To this end, various strategies will be developed, including fucosylation or over-expression of adhesion or immunosuppressive molecules through mRNA transfer or pharmacological treatments of MSCs. The effectiveness of these processes of manipulation of MSCs on GVHD will make it possible to extrapolate their application to other inflammatory and autoimmune diseases of high incidence in the population and with few effective therapeutic options. (English) | |||||||||||||||
| Property / summary: Allogeneic transplantation is the only therapeutic option for many patients with malignant haemopathies. Its results are limited by its high toxicity, with graft-versus-host disease (GHD) being the main cause of morbidity and mortality. GVHD occurs in 30-70 % of patients; of these up to 80 % do not respond or relapse after first line of treatment (corticoids), and their survival does not exceed 15 % in most studies. Mesenchymal stromal cells (MSCs) have been used with mixed results in the treatment of acute GVHD. Some members of this Consortium have developed two previous clinical trials in which they demonstrated that: 1. It is possible to use in clinic MSCs expanded from bone marrow in the absence of bovine serum, which avoids potential risks of zoonoses and 2. since the effect of MSCs on the immune system is transient, sequential administration of MSCs may increase their efficacy. In this sense, it is unknown which is the best administration pattern or which is the best source of MSCs, which can also be easily isolated from adipose tissue (lipoaspirates, usually discarded) (Ad-MSCs). Finally, after infusion, MSCs disappear quickly, so it will be important to increase their therapeutic efficacy through mechanisms that favor their migration and immunosuppressive effect on target organs of GVHD. To this end, various strategies will be developed, including fucosylation or over-expression of adhesion or immunosuppressive molecules through mRNA transfer or pharmacological treatments of MSCs. The effectiveness of these processes of manipulation of MSCs on GVHD will make it possible to extrapolate their application to other inflammatory and autoimmune diseases of high incidence in the population and with few effective therapeutic options. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Allogeneic transplantation is the only therapeutic option for many patients with malignant haemopathies. Its results are limited by its high toxicity, with graft-versus-host disease (GHD) being the main cause of morbidity and mortality. GVHD occurs in 30-70 % of patients; of these up to 80 % do not respond or relapse after first line of treatment (corticoids), and their survival does not exceed 15 % in most studies. Mesenchymal stromal cells (MSCs) have been used with mixed results in the treatment of acute GVHD. Some members of this Consortium have developed two previous clinical trials in which they demonstrated that: 1. It is possible to use in clinic MSCs expanded from bone marrow in the absence of bovine serum, which avoids potential risks of zoonoses and 2. since the effect of MSCs on the immune system is transient, sequential administration of MSCs may increase their efficacy. In this sense, it is unknown which is the best administration pattern or which is the best source of MSCs, which can also be easily isolated from adipose tissue (lipoaspirates, usually discarded) (Ad-MSCs). Finally, after infusion, MSCs disappear quickly, so it will be important to increase their therapeutic efficacy through mechanisms that favor their migration and immunosuppressive effect on target organs of GVHD. To this end, various strategies will be developed, including fucosylation or over-expression of adhesion or immunosuppressive molecules through mRNA transfer or pharmacological treatments of MSCs. The effectiveness of these processes of manipulation of MSCs on GVHD will make it possible to extrapolate their application to other inflammatory and autoimmune diseases of high incidence in the population and with few effective therapeutic options. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 16:44, 12 October 2021
Project Q3161222 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3161222 in Spain |
Statements
14,375.0 Euro
0 references
28,750.0 Euro
0 references
50.0 percent
0 references
1 January 2014
0 references
31 March 2018
0 references
UNIVERSIDAD DE NAVARRA
0 references
42°49'6.42"N, 1°38'39.34"W
0 references
31201
0 references
El trasplante alogénico constituye la única opción terapéutica para numerosos pacientes con hemopatías malignas. Sus resultados se ven limitados por su elevada toxicidad, siendo la enfermedad injerto contra huésped (EICH) la principal causa de morbi-mortalidad. La EICH se produce en 30-70% de los pacientes; de ellos hasta un 80% no responden o recaen tras primera línea de tratamiento (corticoides), y su supervivencia no supera el 15% en la mayoría de estudios. Las células estromales mesenquimales (MSCs) se han empleado con resultados dispares en el tratamiento de la EICH aguda. Algunos miembros de este Consorcio han desarrollado dos ensayos clínicos previos en los que demostraron que: 1. es posible utilizar en clínica MSCs expandidas a partir de médula ósea en ausencia de suero bovino, lo que evitan potenciales riesgos de zoonosis y 2. dado que el efecto de las MSCs sobre el sistema inmune es transitorio, la administración secuencial de MSCs puede aumentar su eficacia. En este sentido, se desconoce cuál es la mejor pauta de administración o cuál es la mejor fuente de MSCs, que pueden aislarse también fácilmente a partir de tejido adiposo (lipoaspirados, que normalmente se desechan) (Ad-MSCs). Finalmente, tras su infusión, las MSCs desparecen rápidamente, por lo que será importante aumentar su eficacia terapéutica mediante mecanismos que favorezcan su migración y efecto inmunosupresor en órganos diana de la EICH. Para ello se desarrollarán diversas estrategias entre las que se incluyen la fucosilación o sobre-expresión de moléculas de adhesión y/o inmunosupresoras mediante transferencia de mRNAs o tratamientos farmacológicos de las MSCs. La eficacia de estos procesos de manipulación de las MSCs sobre la EICH permitirá extrapolar su aplicación a otras enfermedades inflamatorias y autoinmunes de alta incidencia en la población y con pocas opciones terapéuticas eficaces. (Spanish)
0 references
Allogeneic transplantation is the only therapeutic option for many patients with malignant haemopathies. Its results are limited by its high toxicity, with graft-versus-host disease (GHD) being the main cause of morbidity and mortality. GVHD occurs in 30-70 % of patients; of these up to 80 % do not respond or relapse after first line of treatment (corticoids), and their survival does not exceed 15 % in most studies. Mesenchymal stromal cells (MSCs) have been used with mixed results in the treatment of acute GVHD. Some members of this Consortium have developed two previous clinical trials in which they demonstrated that: 1. It is possible to use in clinic MSCs expanded from bone marrow in the absence of bovine serum, which avoids potential risks of zoonoses and 2. since the effect of MSCs on the immune system is transient, sequential administration of MSCs may increase their efficacy. In this sense, it is unknown which is the best administration pattern or which is the best source of MSCs, which can also be easily isolated from adipose tissue (lipoaspirates, usually discarded) (Ad-MSCs). Finally, after infusion, MSCs disappear quickly, so it will be important to increase their therapeutic efficacy through mechanisms that favor their migration and immunosuppressive effect on target organs of GVHD. To this end, various strategies will be developed, including fucosylation or over-expression of adhesion or immunosuppressive molecules through mRNA transfer or pharmacological treatments of MSCs. The effectiveness of these processes of manipulation of MSCs on GVHD will make it possible to extrapolate their application to other inflammatory and autoimmune diseases of high incidence in the population and with few effective therapeutic options. (English)
12 October 2021
0 references
Pamplona/Iruña
0 references
Identifiers
PI13_02188
0 references